Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

P-NET: Pancr. neuroend. tumor

Year of diagnosis	1998-2012
Patients	283
Diseases	283
Creation date	03/20/2014
Export date	02/12/2014
Population	4.5 m



http://www.tumorregister-muenchen.de/en/facts/base/base_hPNETE.pdf

Global Statements about the statistics on the Internet – Baseline Statistics (grey button ——), Survival (red button ——)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.5 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases**** are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.


The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, March 2014

- Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2013 are incorporated into these analyses.
- Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.



ICD-10 codes used for specifying cancer site

Code	Description
C25	Malignant neoplasm of pancreas
C25.0	Head of pancreas
C25.1	Body of pancreas
C25.2	Tail of pancreas
C25.3	Pancreatic duct
C25.4	Endocrine pancreas
C25.7	Other parts of pancreas
C25.8	Overlapping lesion of pancreas
C25.9	Pancreas, unspecified

ICD-O-3 codes (morphology) used for specifying cancer site

Code	Description
8013/3	Large cell neuroendocrine carcinoma
8041/3	Small cell carcinoma, NOS
8150/0	Islet cell adenoma
8150/3	Islet cell carcinoma
8151/3	Insulinoma, malignant
8152/3	Glucagonoma, malignant
8153/3	Gastrinoma, malignant
8155/3	Vipoma, malignant
8156/3	Somatostatinoma, malignant
8240/3	Carcinoid tumor, NOS
8241/3	Enterochromaffin cell carcinoid
8246/3	Neuroendocrine carcinoma, NOS
8249/3	Atypical carcinoid tumor

Reference:

Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System 4th edition, IARC, Lyon (2010).

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

				Prop.		Prop.
		DCO	Prop.	mult.	Prop.	actively
Year of	Cases	cases	DCO	primaries	deaths	followed
diagnosis	n	'n	%	80	%	%
1998	9			22.2	77.8	100.0
1999	6			33.3	50.0	83.3
2000	5				60.0	100.0
2001	4			75.0	50.0	100.0
2002	13			15.4	69.2	100.0 #
2003	14			21.4	64.3	92.9 #
2004	11			27.3	54.5	100.0 #
2005	17			29.4	47.1	100.0 #
2006	14			28.6	64.3	100.0 #
2007	25			24.0	48.0	88.0 # ##
2008	18			27.8	33.3	83.3
2009	26			15.4	61.5	80.8
2010	39			38.5	38.5	76.9
2011	42			16.7	23.8	64.3
2012	40			25.0	12.5	100.0 ###
1998-2012	283			25.1	42.4	86.9

[#] The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

^{##} Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

^{###} Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender including DCO cases

Year of	All	Males	Females	Prop. males	
diagnosis	n	n	n	%	
1998	9 /	6	3	66.7	
1999	6	5	1	83.3	
2000	5	/ 3	2	60.0	
2001	5 4	2	2	50.0	
2002	13	10	3	76.9	
2003	14	6	8	42.9	
2004	/ 11	9		81.8	
2005	17	10	2 7 2	58.8	
2006	14	12	2	85.7	
2007	25	16	9	64.0	
2008	18	7	11	38.9	
2009	26	14	12	53.8	
2010	39	22	17	56.4	
2011	42	22	20	52.4	
2012	40	20	20	50.0	
1998-2012	283	164	119	58.0	

Table 2

Incidence measures by year of diagnosis and gender including DCO cases (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

			Males	Fem.	Males	Fem.	Males	Fem.	Males	Fem.
Year of	Males	Females	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	6	3	0.5	0.3	0.3	0.2	0.5	0.2	0.6	0.3
1999	5	1	0.4	0.1	0.3	0.0	0.4	0.1	0.5	0.1
2000	3	2	0.3	0.2	0.2	0.1	0.2	0.1	0.3	0.1
2001	2	2	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1
2002	10	3	0.5	0.2	0.4	0.0	0.5	0.1	0.5	0.1
2003	6	8	0.3	0.4	0.2	0.3	0.3	0.4	0.3	0.4
2004	9	2 /	0.5	0.1	0.3	0.1	0.4	0.1	0.5	0.1
2005	10	7 <	0.5	0.4	0.3	0.2	0.4	0.3	0.5	0.3
2006	12	2	0.6	0.1	0.4	0.0	0.5	0.1	0.6	0.1
2007	16	9	0.7	0.4	0.5	0.2	0.6	0.3	0.7	0.4
2008	7	11	0.3	0.5	0.2	0.3	0.3	0.3	0.3	0.4
2009	14	12	0.6	0.5	0.4	0.2	0.5	0.4	0.6	0.4
2010	22	17	1.0	0.7	0.5	0.4	0.8	0.6	0.9	0.7
2011	22	20	1.0	0.8	0.6	0.5	0.8	0.6	0.9	0.7
2012	20	20	0.9	0.8	0.5	0.5	0.7	0.6	0.8	0.7
1998-2012	164	119	0.6	0.4	0.4	0.2	0.5	0.3	0.6	0.4




Table 3

Age distribution parameters by year of diagnosis (All) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	9	59.0	14.1	28.2	77.8	28.2	57.0	62.0	63.4	77.8
1999	6	63.8	6.7	53.5	72.2	53.5	59.7	64.9	67.7	72.2
2000	5	57.9	17.5	33,1	74.8	33.1	50.0	57.5	73.9	74.8
2001	4	56.6	12,2	38.6	65.1	38.6	49.3	61.3	63.8	65.1
2002	13	59.9	15.2	36.0	87.6	42.3	49.0	64.3	66.3	83.5
2003	14	58.2	11.1	37.1	77.0	46.6	50.2	56.5	67.3	74.6
2004	11	60.7	12.2	40.8	77.5	46.1	48.3	62.3	74.1	76.2
2005	17	62.9	13.6	36.2	83.5	42.1	55.6	67.8	70.4	77.5
2006	14	58.6	19.3	16.8	78.1	29,1	42.3	64.8	73.1	76.8
2007	25	59.0	12.0	35.3	82.3	44.9	51.2	57.6	69.1	71.5
2008	18	57.6	18.3	23.8	81.2	28.0	47.1	56.8	74.8	79.4
2009	26	66.2	13.2	27.9	85.0	50.2	59.9	67.6	75.3	84.3
2010	39	63.0	12.5	37.5	83.6	46.3	52.5	62.4	74.6	79.0
2011	42	61.9	12.2	34.6	80.5	43.7	52.0	64.6	70.9	74.4
2012	40	63.6	15.1	27.7	101	42.6	57.4	66.2	71.4	79.5
1998-2012	283	61.5	13.8	16.8	101	42.5	52.0	63.4	71.5	77.5

Table 3a

Age distribution parameters by year of diagnosis (MALES)

(incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	6	66.0	7.1	58.9	77.8	58.9	62.0	63.0	71.5	77.8
1999	5	64.7	7.1	53.5	72.2	53.5	62.3	67.5	67.7	72.2
2000	3	60.5	12.2	50.0	73.9	50.0	50.0	57.5	73.9	73.9
2001	2	61.3	1.7	60.1	62.5	60.1	60.1	61.3	62.5	62.5
2002	10	54.2	11.0	36.0	66.8	39.2	46.4	53.1	65.1	66.2
2003	6	63.2	10.4	48.1	77.0	48.1	55.1	64.9	69.2	77.0
2004	9	62.7	12.4	40.8	77.5	40.8	58.7	63.0	74.1	77.5
2005	10	65.3	14.4	36.2	83.5	41.2	62.8	67.8	74.9	80.5
2006	12	56.9	20.5	16.8	78.1	29.1	40.4	60.8	73.9	76.8
2007	16	57.6	9.9	35.3	71.0	44.9	52.0	56.8	66.1	69.8
2008	7	51.0	17.7	28.0	79.4	28.0	35.4	49.3	67.5	79.4
2009	14	65.4	10.7	46.7	84.3	50.2	60.3	67.2	68.9	78.7
2010	22	65.6	11.0	44.6	83.6	52.8	58.0	64.4	74.6	79.0
2011	22	62.2	10.1	43.8	80.5	48.4	52.0	63.5	69.8	73.1
2012	20	63.3	14.8	27.7	84.2	36.6	59.5	68.4	71.4	76.3
1998-2012	164	61.7	12.8	16.8	84.3	44.9	53.4	63.1	70.8	77.0

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	3	45.0	15.0	28.2	57.0	28.2	28.2	49.7	57.0	57.0
1999	1	59.7		59.7	59.7	59.7	59.7	59.7	59.7	59.7
2000	2	54.0	29.5	33,1	74.8	33.1	33.1	54.0	74.8	74.8
2001	2	51.8	18.8	38.6	65.1	38.6	38.6	51.8	65.1	65.1
2002	3	79.1	11.3	66.3	87.6	66.3	66.3	83.5	87.6	87.6
2003	8	54.5	10.8	37.1	74.6	37.1	48.4	55.6	58.0	74.6
2004	2	52.0	8.3	46.1	57.8	46.1	46.1	52.0	57.8	57.8
2005	7	59.4	12.6	42.1	69.6	42.1	42.5	67.8	69.2	69.6
2006	2	68.7	0.2	68.5	68.8	68.5	68.5	68.7	68.8	68.8
2007	9	61.6	15.5	37.8	82.3	37.8	48.9	63.5	71.5	82.3
2008	11	61.8	18.2	23.8	81.2	43.7	48.8	66.9	76.0	78.8
2009	12	67.2	16.0	27.9	85.0	52.2	58.7	72.3	76.9	84.9
2010	17	59.7	13.9	37.5	80.2	43.9	49.2	53.6	72.4	78.4
2011	20	61.5	14.5	34.6	79.2	39.8	45.3	67.2	71.7	76.0
2012	20	63.8	15.7	36.9	101	42.8	56.6	64.8	73.2	82.6
1998-2012	119	61.3	15.1	23.8	101	40.8	48.9	64.0	72.7	78.9



Table 4 $\label{eq:Age} \mbox{Age distribution by 5-year age group and gender for period 1998-2012 } \\ (incl. DCO)$

Age at									
diagnosis	Cases			Males			Females		
Years	n	용	Cum.%	n	96	Cum.%	n	%	Cum.%
15-19	1	0.4	0.4	1	0.6	0.6			0.0
20-24	1	0.4	0.7			0.6	1	0.8	0.8
25-29	5	1.8	2.5	3	1.8	2.4	2	1.7	2.5
30-34	3	1.1	3.5	/ 1	0.6	3.0	2	1.7	4.2
35-39	11	3.9	7.4	5	3.0	6.1	6	5.0	9.2
40 - 44	17	6.0	13.4	7	4.3	10.4	10	8.4	17.6
45-49	23	8.1	21.6	12	7.3	/17.7	11	9.2	26.9
50-54	21	7.4	29.0	15	9.1	26.8	6	5.0	31.9
55-59	32	11.3	40.3	15	9.1	36.0	17	14.3	46.2
60-64	39	13.8	54.1	33	20.1	56.1	6	5.0	51.3
65-69	47	16.6	70.7	29	17.7	73.8	18	15.1	66.4
70-74	39	13.8	84.5	21	12.8	86.6	18	15.1	81.5
75-79	28	9.9	94.3	16	9.8	96.3	12	10.1	91.6
80-84	13	4.6	98.9	6	3.7	100.0	7	5.9	97.5
85+	3	1.1	100.0			100.0	3	2.5	100.0
All ages	283	100.0		164	100.0		119	100.0	

Included in the statistics are 37.8% multiple primaries in males and 25.2% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers for period 1998-2012

Age at diagnosis Years	Males n	Females n	Age- spec.	Females Age- spec. incid.		Females DCO rate n=0 %		Females Prop.all cancers n=142297
0-4			0.0	0.0				
5- 9 10-14			0.0	0.0				
15-14	1		0.0	0.0			0.3	
20-24	_	1	0.0	0.1			0.5	0.2
25-29	3	2	0.2	0.1			0.3	0.2
30-34	1	2	0.0	0.1			0.1	0.1
35-39	5	6	0.2	0.3			0.2	0.2
40 - 44	7	10	0.3	0.4			0.2	0.2
45-49	12	11	0.6	0.5			0.2	0.1
50-54	15	6	0.8	0.3			0.2	0.1
55-59	15	17	0.9	1.0			0.1	0.1
60-64	33	6	2.0	0.3			0.2	0.0
65-69	29	18	2.0	1.1			0.1	0.1
70-74 75-79	21 16	18 12	1.8 2.1	1.3 1.1			0.1 0.1	0.1 0.1
80-84	6	7	1.3	0.8			0.0	0.0
85+	O	3	0.0	0.4			0.0	0.0
031			0.0	0.1				0.0
All ages	164	119			0.0	0.0	0.1	0.1
Incidence								
Raw			0.6	0.4				
WS			0.4					
ES			0.5	0.3				
BRD-S			0.6	0.4				


The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2012

MALES

	Observed Expected	LCL	UCL	DCO
Diagnosis	n n	SIR 95%	95% EAR	. %
C33-C34 Lung	3 0.6	5.4 1.1	15.7 # 68.7	33.3
C61 Prostate	4 / 1.4	3.0 0.8	7.6 74.5	
C64 Kidney	2 0.2	11.7 1.4	42.3 # 51.5	
Other primaries	1 0.2	5.5 0.1	30.9 23.1	
Not observed	0 2.4	0.0 0.0	1.5 -68.1	
All mult. primaries	10 4.7	2.1 1.0	3.9 # 149.6	10.0



The occurrence of second malignancy is statistically significant.


Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2012

FEMALES

Diagnosis	Observed E	xpected n	SIR	LCL 95%	UCL 95%	EAR	DCO %
C50 Breast	2	0.6	3.5	0.4	12.5	68.7	
Other primaries Not observed	3 0	0.2	14.8	3.0	43.2 # 3.6	135.1 -49.0	66.7
All mult. primaries	/ 5	1.8	2.8	0.9	6.5	154.7	40.0



The occurrence of second malignancy is statistically significant.

Observed second malignancies with count 1 are pooled in category "Other primaries".

P-NET: Pancreatic neuroendocrine tumor




Figure 7. Age distribution and age-specific incidence



P-NET: Pancreatic neuroendocrine tumor




Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).



Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.





Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.



Average incidence (world standard population) 2003 - 2008: Males



Average incidence (world standard population) 2003 - 2008: Females





Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.3/100,000 WS N=58, females 0.2/100,000 WS N=37). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women were identified with newly diagnosed pancr. neuroend. tumor. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.4/100,000.

Standardized incidence ratio (SIR) 2003 - 2008: Males



0.5 0.25 0

Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=58, females N=37). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women were identified with newly diagnosed pancr. neuroend. tumor. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.87. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 6.44, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

		Prop.				Prop. deaths
	Incident	actively	Prop.		Prop.	with death
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	%	%	n	%	%
1998	9	100.0		7	77.8	85.7
1999	6	83.3		3	50.0	100.0
2000	5	100.0		3	60.0	100.0
2001	4	100.0		2	50.0	100.0
2002	13	100.0		9	69.2	88.9
2003	14	92.9		9	64.3	100.0
2004	11/	100.0		6	54.5	100.0
2005	1/7	100.0		8	47.1	100.0
2006	14	100.0		9	64.3	100.0
2007	25	88.0		12	48.0	100.0
2008	18	83.3		6	33.3	100.0
2009	26	80.8		16	61.5	93.8
2010	39	76.9		15	38.5	100.0
2011	42	64.3		10	23.8	100.0
2012	40	100.0		5	12.5	80.0
1998-2012	283	86.9		120	42.4	96.7

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis (incl. DCO)

			Prop.		
			deaths		Prop.
Year of	Incident		with death	Deaths in	deaths in
diagnosis/	cases	Deaths	certific.	same year	same year
death	n	/ n /	%	n	%
1998	9	/ 2	50.0	1	11.1
1999	6	6	100.0	2	33.3
2000	5	3	100.0	1	20.0
2001	4	3	100.0		
2002	13	6	100.0	/ 1	7.7
2003	14	7	100.0	2	14.3
2004	11	6	100.0	1	9.1
2005	17	6	100.0	3	17.6
2006	14	7	100.0	2	14.3
2007	25	14	100.0	4	16.0
2008	18	9	100.0	1	5.6
2009	26	12	91.7	7	26.9
2010	39	17	94.1	3	7.7
2011	42	17	100.0	5	11.9
2012	40	15	100.0	4	10.0
1998-2012	283	130	97.7	37	13.1

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-related deaths, and cancer recorded on death certificates (incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

				Prop. cancer	
		Prop.	Prop.	recorded	
		cancer-	not cancer-	on death	
Year of	Deaths	related	related	certificate	
death	n	%	96	8	
1998	2	100.0		100.0	
1999	2 6	100.0		100.0	
2000	3	100.0		100.0	
2001	3	100.0		100.0	
2002	6	100.0		83.3	
2003	7	100.0		100.0	
2004	6	83.3	16.7	83.3	
2005	6	100.0		100.0	
2006	7	100.0		100.0	
2007	14	92.9	7.1	92.9	
2008	9	88.9	11.1	88.9	
2009	/ 12	83.3	16.7	90.9	
2010	17	88.2	11.8	81.3	
2011	17	82.4	17.6	94.1	
2012	15	93.3	6.7	86.7	
1998-2012	130	91.5	8.5	91.3	

Table 11a $\begin{tabular}{ll} Means of age at death according to the grouping in Table 10 \\ \hline MALES \end{tabular}$

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(not cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998	2	71.9	71.9		65.7
1999	6	61.3	61.3		61.3
2000	2	59.5	59.5		59.5
2001	1	64.6	64.6		64.6
2002	5	66.1	66.1		65.3
2003	4	64.8	64.8		64.8
2004	3	66.7	66.7		66.7
2005	5	72.5	72.5		72.5
2006	7	69.3	69.3		69.3
2007	6	62.5	62.5		62.5
2008	6	55.6	55.6		55.6
2009	5	55.6	58.7	43.5	58.7
2010	10	73.3	72.9	75.1	72.5
2011	8	68.6	68.6		68.6
2012	10	64.6	65.1	59.7	64.2
1998-2012	80	65.6	65.7	63.4	65.3

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b Means of age at death according to the grouping in Table 10 FEMALES

Year of death	Deaths n	Age at death (all causes)	Age at death (cancer-related) Years	Age at death (not cancer- related) Years	Age at death (according to death certificate) Years
1998					
1999		_/ /			/
2000	1	54.7	54.7		54.7
2001	2	69.9	69.9		69.9
2002	1	66.4	66.4		66.4
2003	3	39.8	39.8		39.8
2004	3	58.5	54.8	65.9	54.8
2005	1	90.8	90.8		90.8
2006					
2007	8	63.8	65.9	48.9	65.9
2008	3	74.9	71.5	81.8	71.5
2009	7	67.2	64.0	86.8	64.0
2010	7 /	61.4	61.4		61.8
2011	9 5	67.4	64.9	72.4	67.7
2012	5	68.1	68.1		68.1
1998-2012	50	64.6	63.5	71.5	64.1

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a $\begin{tabular}{ll} Mortality measures (cancer-related death) and mortality-incidence-index \\ by year of death \\ \hline MALES \\ \end{tabular}$

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	2	0.2	0.33	0.1	0.34	0.2	0.38	0.2	0.44
1999	6	0.5	1.20	0.3	1.14	0.4	1.06	0.5	1.04
2000	2	0.2	0.67	0.1	0.75	0.2	0.71	0.2	0.67
2001	1	0.1	0.50	0.0	0.50	0.1	0.50	0.1	0.50
2002	5	0.3	0.50	0.2	0.43	0.2	0.44	0.2	0.45
2003	4	0.2	0.67	0.1	0.63	0.2	0.65	0.2	0.69
2004	3	0.2	0.33	0.1	0.30	0.1	0.33	0.2	0.35
2005	5	0.3	0.50	0.1	0.43	0.2	0.47	0.3	0.53
2006	7	0.4	0.58	0.2	0.40	0.3	0.48	0.3	0.53
2007	6	0.3	0.38	0.2	0.34	0.2	0.36	0.3	0.44
2008	6	0.3	0.86	0.2	0.95	0.3	0.94	0.3	0.90
2009	4	0.2	0.29	0.1	0.34	0.2	0.33	0.2	0.28
2010	8	0.4	0.36	0.2	0.30	0.3	0.34	0.4	0.39
2011	8	0.4	0.36	0.2	0.31	0.3	0.32	0.3	0.35
2012	9	0.4	0.45	0.2	0.44	0.3	0.45	0.4	0.44
1998-2012	76	0.3	0.46	0.2	0.43	0.2	0.45	0.3	0.47

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index by year of death

FEMALES

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998									
1999									
2000	1	0.1	0.50	0.1	0.63	0.1	0.68	0.1	0.57
2001	2	0.2	1.00	0.1	0.87	0.1	0.98	0.2	1.11
2002	1	0.1	0.33	0.0	0.62	0.0	0.52	0.0	0.41
2003	3	0.2	0.38	0.1	0.47	0.1	0.38	0.2	0.38
2004	2	0.1	1.00	0.1	0.96	0.1	0.88	0.1	0.92
2005	1	0.1	0.14	0.0	0.05	0.0	0.07	0.0	0.09
2006									
2007	7	0.3	0.78	0.2	0.72	0.2	0.75	0.3	0.75
2008	2	0.1	0.18	0.0	0.16	0.1	0.18	0.1	0.20
2009	6	0.3	0.50	0.1	0.55	0.2	0.54	0.2	0.47
2010	7	0.3	0.41	0.2	0.43	0.2	0.40	0.3	0.41
2011	6	0.3	0.30	0.1	0.26	0.2	0.27	0.2	0.30
2012	5	0.2	0.25	0.1	0.22	0.2	0.24	0.2	0.24
1998-2012	43	0.1	0.36	0.1	0.35	0.1	0.35	0.1	0.36

Table 13

Age distribution of age at death (cancer-related) for period 1998-2012 (incl. multiple primaries)

Age at									
death	Cases			Males			Females		
Years	n	%	Cum.%	n	%	Cum.%	n	%	Cum.%
15-19	1	0.8	0.8	1	1.3	1.3			0.0
20-24	0	0.0	0.8			1.3			0.0
25-29	2	1.7	2.5			1.3	2	4.7	4.7
30-34	0	0.0	2.5			1.3			4.7
35-39	3	2.5	5.0	2	2.6	3.9	1	2.3	7.0
40-44	3	2.5	7.6	1	1.3	5.3	2	4.7	11.6
45-49	4	3.4	10.9			5.3	4	9.3	20.9
50-54	12	10.1	21.0	6	7.9	13.2	6	14.0	34.9
55-59	9	7.6	28.6	6	7.9	21.1	3	7.0	41.9
60-64	20	16.8	45.4	17	22.4	43.4	3	7.0	48.8
65-69	24	20.2	65.5	19	25.0	68.4	5	11.6	60.5
70-74	15	12.6	78.2	8	10.5	78.9	7	16.3	76.7
75-79	14	11.8	89.9	10	13.2	92.1	4	9.3	86.0
80-84	8	6.7	96.6	5	6.6	98.7	3	7.0	93.0
85+	4	3.4	100.0	1	1.3	100.0	3	7.0	100.0
All ages	119	100.0		76	100.0		43	100.0	

Included in the statistics are 37.8% multiple primaries in males and 25.2% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012 (incl. multiple primaries)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	_ /		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0 - 4			0.0		0.0			
5- 9			0.0		0.0			
10-14	_		0.0		0.0			
15-19	1		0.1	1.00	0.0		2.4	
20-24		_ /	0.0		0.0			
25-29		2	0.0		0.1	1.00		1.8
30-34	•		0.0	0.40	0.0	/		
35-39	2	1	0.1	0.40	0.0	0.17	0.5	0.2
40-44	1	2	0.0	0.14	0.1		0.1	0.2
45-49		4	0.0	0.40	0.2		0 0	0.2
50-54	6	6	0.3		0.3	1.00	0.2	0.2
55-59	6	3	0.4		0.2		0.1	0.1
60-64	17	3	1.0		0.2		0.2	0.0
65-69	19	5	1.3		0.3		0.2	0.1
70-74	8	7	0.7		0.5	0.39	0.1	0.1
75-79	10	4	1.3		0.4		0.1	0.0
80-84	5	3	1.1		0.3		0.1	0.0
85+	1	3	0.3	1.00	0.4	1.00	0.0	0.0
711 200	76	43					0.1	0.1
All ages	76	43					0.1	0.1
Mortality								
Raw			0.3	0.46	0.1	0.36		
WS			0.3		0.1			
ES			0.2		0.1			
BRD-S			0.2	0.47	0.1			
DRD 5			0.3	0.17	0.1	0.30		
PYLL-70								
per 100,000			2.0		1.8			
ES			1.8		1.6			
AYLL-70			9.6		16.9			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.



Table 15a

Multiple primaries in deaths in period 1998-2012

MALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	% ↓	n	←%	n	~%	n	← %
_								
C16 Stomach	4	16.7	4	100.0				
C18 Colon	/2	8.3	1	50.0	\ 1	50.0		
C19-C20 Rectum	/ 1	4.2			1	100.0		
C23-C24 Bile	/ 1	4.2	1	100.0				
C25 Pancreas	/ 1	4.2			1	100.0		
C33-C34 Lung	/ 2 /	8.3	1	50.0			1	50.0
C43 Malign. melanoma	_ 2 _	8.3	2	100.0				
C44 Skin others	1	4.2	1	100.0				
C61 Prostate	6	25.0	5	83.3			1	16.7
C64 Kidney	1	4.2	1	100.0				
C67 Bladder	1	4.2	1	100.0				
C70-C72 CNS cancer	2	8.3					2	100.0
All mult. primaries	24	100.0	17	70.8	3	12.5	4	16.7




Table 15b

Multiple primaries in deaths in period 1998-2012
FEMALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n	% ↓	n	← %	n	%→	n	← %
C16 Stomach	1	14.3					1	100.0
C23-C24 Bile	1 /	14.3			1	100.0		
C33-C34 Lung	3	42.9	1	33.3			2	66.7
C50 Breast	1 /	14.3					1	100.0
C73 Thyroid	1/	14.3	1	100.0				
All mult. primaries	7	100.0	2	28.6	1/	14.3	4	57.1



ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012

(Singular primaries only *)

Age at death	Males	Females	Males Age- spec.		Females Age- spec.		Males Prop.all cancers	Females Prop.all cancers
Years	n	n		MI-index		MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19	1		0.1	1.00	0.0		2.6	
20-24			0.0		0.0			
25-29		2 /	0.0		0.1	1.00		1.9
30-34			0.0		0.0			
35-39	2	1	0.1	0.40	0.0	0.17	0.6	0.2
40-44	1	2	0.0	0.17	0.1	0.22	0.1	0.2
45-49		3	0.0		0.1	0.30		0.2
50-54	6	6	0.3	0.40	0.3	1.20	0.2	0.2
55-59	4	2	0.2	0.36	0.1	0.15	0.1	0.1
60-64	15	3	0.9	0.56	0.2	0.50	0.2	0.1
65-69	16	5	1.1	0.73	0.3	0.29	0.2	0.1
70-74	6	7	0.5	0.50	0.5	0.50	0.1	0.1
75-79	4	3	0.5	0.40	0.3	0.30	0.0	0.0
80-84	5	3	1.1	1.00	0.3	0.75	0.1	0.0
85+	1	3	0.3	1.00	0.4	1.50	0.0	0.0
All ages	61	40					0.1	0.1
Mortality								
Raw			0.2		0.1	0.40		
WS			0.1	0.45	0.1	0.37		
ES			0.2		0.1	0.38		
BRD-S			0.2	0.48	0.1	0.39		
PYLL-70								
per 100,000			1.8		1.7			
ES			1.7		1.5			
AYLL-70			10.1		16.9			
, 0								

^{*} See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012

(Single primaries only *)

Age at			Males Age-		Females Age-		_	Females Prop.all
death		Females	spec.	NOT - 1	spec.	NOT ' 1	cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	્રે	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19	1		0.1	1.00	0.0		2.6	
20-24	_		0.0		0.0		_,,	
25-29		2	0.0		0.1	1.00		2.1
30-34			0.0		0.0			
35-39	2	1	0.1	0.40	0.0	0.25	0.6	0.2
40-44	1	2	0.0	0.17	0.1	0.22	0.1	0.2
45-49		2	0.0		0.1	0.22		0.1
50-54	6	6	0.3	0.43	0.3	1.20	0.2	0.3
55-59	4	2	0.2	0.36	0.1	0.15	0.1	0.1
60-64	14	3	0.8	0.58	0.2	0.60	0.2	0.1
65-69	15	3	1.0	0.75	0.2	0.20	0.2	0.1
70-74	5	7	0.4	0.45	0.5	0.54	0.1	0.1
75-79	4	3	0.5	0.44	0.3	0.30	0.1	0.0
80-84	5	3	1.1		0.3	1.00	0.1	0.0
85+	1	2	0.3	1.00	0.2	1.00	0.0	0.0
All ages	58	36					0.1	0.1
Mortality								
Raw			0.2		0.1	0.39		
WS			0.1	0.46	0.1	0.37		
ES			0.2		0.1	0.37		
BRD-S			0.2	0.49	0.1	0.38		
PYLL-70								
per 100,000			1.8		1.5			
ES ES			1.6		1.4			
AYLL-70			10.3		18.0			
· · ·								

^{*} See corresponding tables with multiple primaries.

P-NET: Pancreatic neuroendocrine tumor





Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at pancr. neuroend. tumor-related death (see Table 10) should be considered.



Average mortality (world standard population) 2003 - 2008: Males



Average mortality (world standard population) 2003 - 2008: Females





Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.2/100,000 WS N=31, females 0.1/100,000 WS N=14). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from pancr. neuroend. tumor. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.4/100,000.

Standardized mortality ratio (SMR) 2003 - 2008: Males



0.5 0

Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=31, females N=14). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from pancr. neuroend. tumor. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 2.37. Though, the value of this parameter may vary with an underlying probability of 99% between 0.01 and 17.61, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

AYLL-70 Average years of life lost prior to age 70 given a person dies before that age

BRD-S German standard population

DCO Death certificate only EAR Excess absolute risk

= excess cancer cases (O - E) per 10,000 person-years

ES European standard population (old) FRG Federal Republic of Germany

GEKID Association of Population-based Cancer Registries in Germany

(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)

LCL Lower confidence limit

MI-index Ratio between mortality and incidence

MCR Munich Cancer Registry (Tumorregister München)

PYLL-70 Potential years of life lost prior to age 70 given a person dies before that age

SEER Surveillance, Epidemiology, and End Results (USA)

SIR Standardized incidence ratio
SMR Standardized mortality ratio
UCL Upper confidence limit
WS World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics P-NET: Pancr. neuroend. tumor [Internet]. 2014 [updated 2014 Mar 20; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_hPNETE.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl	l.	Page
1	Pts cohorts, DCO, mult. prim., follow-up / yr	4
1a	Gender distribution by year of diagnosis	5
2	Incidence by year of diagnosis	6
3	Age distribution parameters by year of diagnosis	7
4	Age distribution by 5-year age group and gender	9
5	Age-specific incidence and DCO rate	10
6	Standardized incidence ratio of second primaries	11
7	Age distribution and age-specific incidence (chart)	13
7a	Age-specific incidence internationally (chart)	14
8	Cumulative follow-up years (chart)	15
9a	Map of cancer incidence (WS) by county (chart)	16
9b	Standardized incidence ratio (SIR) by county (chart)	17
10a	Pts incident cohorts and mortality / yr	18
10b	Incidence and mortality by year of diagnosis	19
10c	Cancer-related deaths, death certification available / yr	20
11	Means of age at death / yr	21
12	Mortality by year of death	23
13	Distribution of age at death	24
14	Age-specific mortality	25
15	Multiple primaries in deaths	26
16	Age-specific mortality (first primaries)	28
17	Age-specific mortality (single primaries)	29
18	Age distribution and age-specific mortality (chart)	30
19a	Map of cancer mortality (WS) by county (chart)	31
19b	Standardized mortality ratio (SMR) by county (chart)	32